Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2026 | BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial

Kalijn Bol, MD, Radboud University Medical Center, Nijmegen, Netherlands, presents findings from the Phase II COWBOY trial (NCT02968303) examining induction vemurafenib with cobimetinib prior to immunotherapy with nivolumab and ipilimumab in patients with BRAF V600E/K mutated melanoma and elevated LDH compared with upfront immunotherapy. The trial was terminated prematurely due to slow patient accrual, however analysis from the more than 70 randomized patients showed a lower response rate in the induction group compared with the upfront immunotherapy group. Survival curves for progression-free survival and overall survival also favor upfront immunotherapy. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.